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Abstract 
Background: Gestational diabetes mellitus (GDM) is a risk factor for the development of diabetes mellitus (DM). 
However, there is a low return rate for this screening, so it is important to search for earlier methods for evaluation 
after delivery, to increase the number of pregnant women screened, so you can start the treatment or prevention of 
these early comorbidities. To determine the accuracy of the 75 g 2-h oral glucose tolerance test (OGTT) performed 
between 48–72 h after delivery for the diagnosis of DM using the OGTT after 6 weeks as the gold standard criterion, 
and to identify the optimal cutoff points for this exam for diabetes screening after a pregnancy complicated by GDM.
Methods: 82 women with previous GDM underwent an OGTT between 48–72 h postpartum and repeated the test 
6 weeks after delivery.
Results: The prevalence of DM and prediabetes based on the first OGTT was 3.7 and 32.9 %, respectively, and 8.5 
and 20.7 %, respectively, at the second OGTT. For those with DM, the area under the curve (AUC) based on the 
fasting plasma glucose (FPG) was 0.77 (95 % CI 0.61–0.92), and based on 2-h OGTT was 0.82 (95 % CI 0.66–0.97). For 
patients with prediabetes, the AUC based on the FPG was 0.73 (95 % CI 0.59–0.86) and based on the 2-h OGTT was 
0.74 (95 % CI 0.61–0.87). Using a FPG cutoff value of 78 mg/dl (4.3 mmol/L) and a 2-h OGTT cutoff value of 130 mg/
dl (7.2 mmol/L) for DM, the specificity was 58.7 and 60 %, the sensitivity was 71.4 and 85.7 %, the positive predictive 
value was 13.9 and 16.7 and the negative predictive value was 95.7 and 97.9 %, respectively.
Conclusions: OGTT performed early in postpartum is a useful tool for identifying women with previous GDM who 
must perform an OGTT 6 weeks after delivery.
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Background
The number of patients with diabetes mellitus (DM) has 
increased significantly in recent decades. Despite better 
awareness and developments in treatment and preven-
tion of type 2 diabetes, one in two adults with diabetes is 
undiagnosed [1]. The increasing prevalence of overweight 
and obesity in both developed and developing countries 
are the main factors for this rise [2]. Likewise, a growing 
number of cases of gestational diabetes mellitus (GDM) 
have been described in the last decades [3].
The frequency of GDM varies between 3–14 % depend-
ing on the method used for diagnosis and the study 
population [4–7]. The magnitude of the risk of postpar-
tum diabetes depends on the ethnicity, the duration of 
follow up and the specific criteria for GDM diagnosis. 
Studies have shown that 3–65  % of women with previ-
ous GDM develop type 2 diabetes within 5–16 years after 
the index pregnancy [8–13]. When screened 6–12 weeks 
postpartum, up to 10 % of women who had GDM were 
diagnosed with diabetes and an additional 12–36 % had 
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[14, 15]. Postpartum screening aims to identify women 
that developed or have an elevated risk of developing 
diabetes after pregnancy. Early recognition is impor-
tant because lifestyle modifications and medications can 
reduce the incidence of diabetes in individuals at high 
risk [16–18]. Additionally, the early treatment of diabetes 
can prevent or delay microvascular end organ complica-
tions and reduce the risk of experiencing complications 
in subsequent pregnancies [19–23].
Both the American Diabetes Association (ADA) and 
the World Health Organisation (WHO) recommend 
postpartum screening after 6–12  weeks, using the 75  g 
2-h oral glucose tolerance test (OGTT) [24–26]. The 
United Kingdom’s National Institute for Health and Clin-
ical Excellence (NICE) recommends the fasting plasma 
glucose (FPG) test be administered at least 6 weeks after 
childbirth, instead of the traditional OGTT [27, 28]. The 
OGTT is more sensitive, with reported sensitivities of 
100  % compared with 67  % for the FPG [29]. Previous 
studies of postpartum diabetes screening in women with 
GDM-affected pregnancies have noted test completion 
rates that range from 14–61 % [15, 20, 30, 31]. Alterna-
tive diagnostic tools may increase the number of evalu-
ated women with previous GDM. The ADA recommends 
that women with a history of GDM with a normal post-
partum screening might be rescreened every 3 years, and 
women with impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT) or both (prediabetes) should be 
rescreened annually [18].
The purpose of this study was to determine the accu-
racy of the 2-h OGTT performed between 48–72 h after 
delivery for the diagnosis of diabetes and to identify the 
optimal 2-h OGTT cutoff points for screening dysglycae-
mia in the early postpartum period using the follow-up 
2-h OGTT after 6 weeks as the gold standard criteria.
Methods
Study design
In this prospective observational study, women with 
previous GDM who were recruited from a multi-ethnic 
population were evaluated. The diagnosis of GDM in 
pregnant women prior to December 2010 was made 
according to the Carpenter and Coustan criteria [32]; 
after January 2011, the diagnosis was made according 
to the International Association of Diabetes and Preg-
nancy Study Groups (IADPSG) [33]. The inclusion cri-
teria were pregnant women diagnosed with GDM with 
regular follow-up in the diabetes and pregnancy outpa-
tient clinic of the maternity school at Rio de Janeiro Fed-
eral University. Women who used medications known to 
affect glucose metabolism, and mothers diagnosed with 
GDM who were discharged before 48  h after delivery 
were excluded (8.1 %). All women identified with GDM 
underwent self-monitoring of blood glucose measure-
ments, as well as dietary management. Insulin treatment 
was initiated when dietary management did not achieve 
the glycaemic goal (fasting blood glucose >95 mg/dl, 1 h 
postprandial blood glucose >140 mg/dl, or 2 h postpran-
dial blood glucose >120 mg/dl). The standard care was to 
screen all pregnant women with previous GDM with the 
2-h OGTT at six weeks after delivery.
Data collection included a detailed clinical and obstet-
ric history. Measurements of FPG and a 2-h OGTT 
were assessed using an enzymatic colorimetric method 
between 48–72 h and 6 weeks after delivery. Study sub-
jects were instructed to fast overnight for at least 8  h 
prior to their testing day and to eat at least 150 g of car-
bohydrate the day prior to testing. The OGTT used a 75 g 
anhydrous glucose load and followed the standard WHO 
procedures [34]. The diagnostic categories of normal, 
prediabetes (i.e., impaired fasting glucose or impaired 
glucose tolerance) and diabetes were determined from 
the results of the FPG and 2-h OGTT using the WHO 
2006/ADA criteria [35].
Ethical considerations
All participants provided written informed consent. The 
Local Ethics Committee approved this study.
Statistical analysis
Statistical analyses were performed with SPSS version 
20.0. Differences in the classifications between normal, 
prediabetes and diabetes using the FPG and OGTT 
were assessed using a non-parametric test (Wilcoxon). 
Receiver operating characteristic (ROC) curves were 
developed, and the area under the curve (AUC) with 95 % 
CIs was determined. The ROC curves were constructed 
to calculate the sensitivity, specificity, predictive value 
positive and predictive value negative at different cutoff 
values. The optimal FPG and 2 h OGTT-screening cutoff 
points between 48–72  h after delivery were determined 
by taking the greatest sum of the sensitivity and specific-
ity for the measured FPG and 2-h OGTT values between 
the two diagnosed groups (diabetes and prediabetes). 
The positive predictive value was defined as the number 
of true positives divided by the total number of individu-
als who tested positive, whereas the negative predictive 
value referred to the proportion of subjects with a nega-
tive test result who were correctly diagnosed. The posi-
tive predictive value and negative predictive value were 
also reported for the optimal cutoff values.
Results and discussion
During the inclusion period, 257 women with GDM 
were identified; however, only 82 (31.9  %) patients met 
all inclusion criteria, had full laboratory data for analysis, 
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and were included in the study. In fact, 21 mothers were 
discharged before 48  h (8.1  %), 49 patients did only the 
first OGTT (19 %), and 105 did not return to the second 
OGTT (40, 85 %). Perinatal features of this study cohort 
were as follows: the mean age was 32.2 (± 5.8) years, the 
mean body mass index (BMI) was = 27.7 (±5.3) kg/m2, 
54.4 % were non-caucasian, 56.7 % had more than 8 years 
of education and 68.4  % had a relative with DM. Addi-
tionally, the mean parity of the women was 2.3 (±1.3), the 
mean gestational age at GDM diagnosis was 23.1 weeks 
(±7.4), 69.4  % had a caesarean delivery and 64.6  % 
required insulin treatment (Table 1).The mean FPG levels 
in the early period (48–72 h) after delivery were 76.7 mg/
dl (4.26  mmol/L  ±  0.66), whereas the mean FPG lev-
els after 6  weeks were 92.6  mg/dl (5.1  mmol/L ±  15.7) 
(p  <  0.0001). All patients were breastfeeding during 
routine postpartum OGTT. The 2  h post-load glucose 
was 123.6  mg/dl (6.8  mmol/L  ±  2.0) and 110.0  mg/dl 
(6.1  mmol/L (±2.2) (p  =  0.001) between 48–72  h and 
after 6  weeks, respectively. The prevalence of diabetes 
and prediabetes based on the 75  g OGTT performed 
at 48–72  h after birth was 3.7 and 32.9  %, respectively, 
whereas the prevalence based on the second OGTT was 
8.5 and 20.7 %, respectively.
Women with diagnosis of diabetes on the second 75 g 
OGTT (n = 7) had mean age of 33.1 (±6.4) years and the 
mean BMI was 29.8 (±7.2) kg/m2 respectively. In addi-
tion, the mean parity was 2.4 (±1.6), and the mean ges-
tational age at GDM diagnosis was 19.4 (±8.7). These 
patients had a mean weight gain until the GDM diagnosis 
of 5.1 (±3.8) kg and 8.2 (±2.9) kg until delivery. Eighty-
five percent were on using insulin at an average of 27.3 
(±2.9) weeks, and seventy-one percent had a family his-
tory of DM. The delivery was on average 37.5 (±5.2) 
weeks and the neonate’s weight was 3108.3 (±957.2) g. 
There was no statistically significant difference between 
mothers with and without a diagnosis of diabetes 
postpartum.
Using the 2-h value of 200 mg/dl (11.1 mmol/L) as the 
cutoff for identifying individuals with diabetes resulted in 
a sensitivity of 28.6 %, a specificity of 98.7 % and positive 
and negative predictive values of 66.7 and 93.7 %, respec-
tively. The performance of the early 2-h OGTT was also 
evaluated using 140 mg/dl (7.7 mmol/L) as the cutoff for 
identifying individuals with prediabetes, which revealed 
a sensitivity of 64.7  %, a specificity of 75.4  % and posi-
tive and negative predictive values of 40.7 and 89.1  %, 
respectively.
The AUC based on the FPG in the early period for 
the group with diabetes was 0.77 (95  % CI 0.61–0.92; 
p = 0.020) and 0.82 (95 % CI 0.66–0.97; p = 0.006) based 
on the 2-h OGTT (Fig. 1). The AUC based on the FPG in 
the early period for the group with prediabetes was 0.73 
(95  % CI 0.59–0.86 p =  0.004) and 0.74 (95  %CI 0.61–
0.87; p  =  0.002) based on the 2-h OGTT (Fig.  1). The 
greatest accuracy for prediabetes was found with the cut-
off values of 78 mg/dl (4.3 mmol/L) for FPG and 130 mg/
dl (7.2 mmol/L) for the 2-h OGTT (specificity was 63.1 
and 64.6 %, sensitivity was 70.6 and 76.5 %, the positive 
predictive value was 33.3 and 36.1  % and the negative 
predictive value was 89.1 and 91.3  %, respectively). The 
greatest accuracy for diabetes was found with the cutoff 
values of 80 mg/dl (4.4 mmol/L) for the FPG and 150 mg/
dl (8.33 mmol/L) for the 2-h OGTT (the specificity was 
66.7 and 80  %, the sensitivity was 71.4  % for both, the 
positive predictive value was 16.7 and 25 % and the nega-
tive predictive value was 96.2 and 96.8  %, respectively) 
(Table 2).
The mean age of women not included in the study 
(n  =  175) were 30.5 (±5.8) years and the mean age of 
pregnancy at GDM diagnosis were 23.9 (±7.4) weeks, 
with an average BMI of 28.4 (±5.1) kg/m2. In addition, 
Table 1 Patient characteristics
Characteristics Mean ± SD or %
Age (years) 32.2 ± 5.8
Gestational age at diagnosis (weeks) 23.1 ± 7.4
Parity (n) 2.3 ± 1.3
Weight gain until delivery (kg) 10.2 ± 6.3
Pre-pregnancy BMI (kg/m2) 27.7 ± 5.3
Gestational age at birth (weeks) 37.8 ± 2.9
Fig. 1 Receiver operating characteristics curve for the FPG and 2 h 
OGTT used for the detection of diabetes by glucose criteria. a Early 
FPG for DM. b Early 2-h OGTT for DM. c Early FPG for Pre DM. d Early 
2-h OGTT for Pre DM
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57.5 % were on insulin and 65.4 % had a family history of 
diabetes. Comparing both groups (women included and 
not included in the study), there was no statistically dif-
ference in continuous sociodemographic variables. Con-
cerning the categorical variables, the history of previous 
GDM in the mothers included in the study was signifi-
cantly higher than in the group of mothers not included 
(23.4 ×  7.9  %, p =  0.008). There was no significant dif-
ference in other categorical variables between the two 
groups (Tables 3, 4).
We compared the influence of the type of delivery 
(Vaginal vs Cesarean section) on serum levels of fasting 
glucose and post-load 75 g, both in collecting 48–72 h as 
in collecting six weeks, and no statistically significant dif-
ference was found.
Discussion
To our knowledge, this is the first study that evaluate 
the accuracy and cut off values of OGTT during the 
early postpartum period in women still hospitalised 
with previous GDM for determine DM risk. Recently, 
a study was published and evaluated 58 women with 
previous GDM who agreed to perform the 75 g OGTT 
on the second day postpartum. These results were 
compared with the standard 75  g OGTT 4–12  weeks 
postpartum. Only 49 of the 98 women presented for 
routine postpartum OGTT. This study concludes that 
performing OGTT on the second day is feasible and 
should be further investigated as an alternative post-
partum testing regimen in GDM [36]. In this present 
study, a 48–72 h OGTT was proven to be a useful tool 
for identifying women who must perform an OGTT 
at 6  weeks after delivery. We determined that a FPG 
of 78  mg/dl (4.3  mmol/L) or a 2-h OGTT of 130  mg/
dl (7.2 mmol/L) were the optimal screening cutoff lev-
els for prediabetes, whereas 80 mg/dl (4.4 mmol/L) or 
150  mg/dl (8.3  mmol/L), respectively, were the opti-
mal screening cutoff levels for diabetes. Thus, a FPG 
of 78 mg/dl (4.3 mmol/L) and a 2-h OGTT of 130 mg/
dl (7.2  mmol/L) provide the optimal cutoffs to screen 
for dysglycemia after GDM complicated pregnancies. 
Additionally, we determined that the 2  h OGTT was 
more accurate than the FPG.
It is important for screening tests to miss fewer indi-
viduals with the target disease, and therefore, screen-
ing cutoffs are typically lower compared with diagnostic 
cutoffs. Differences may also result from interference 
related to the hormonal changes that occur during this 
postpartum period [37–39]. A special hormonal milieu 
is observed between 48–72  h after birth. During preg-
nancy, the levels of oestrogen and progesterone increase 
greatly primarily because of placental production [40–
43]. Following the removal of the placenta, these hor-
mones fall sharply and reach pre-pregnancy levels on 
the fifth day postpartum [44]. Levels of cortisol, beta- 
endorphin, and β-HCG also decline during this period 
[45]. In women who do not breastfeed, prolactin returns 
to pre-pregnancy levels by 3  weeks after delivery [46]. 
These hormones, which are counter-regulatory to insu-
lin, contribute to increased insulin resistance in the early 
postpartum period. Although the OGTT at 48–72  h 
did not appear to define the diagnosis of diabetes in 
this study, it was notable that the OGTT at 48–72  h 
had a high negative predictive value, with a cutoff 
FPG <78 mg/dl (4.3 mmol/L) and 2-h OGTT <130 mg/
dl (7.2  mmol/L), thereby excluding nearly all individu-
als with diabetes (but not prediabetes). Moreover, dia-
betes-screening cutoffs that included an early FPG of 
78  mg/dl (4.3  mmol/L) and a 2  h OGTT of 130  mg/dl 
(7.2  mmol/L) effectively identified higher-risk individu-
als who required a referral for additional evaluation and 
management. Using these cutoff points, it was found 
that only 37 % of women should be advised to have their 
glucose tolerance assessed 6 weeks after delivery. Thus, 
more than half of women (63 %) should be reevaluated 
only after 1–3 years per the ADA guidelines on the fre-
quency of testing [18]. Furthermore, identifying women 
that should return at 6 weeks eases the overall burden to 
health-care practitioners and reduces the effort required 
to contact patients and, if necessary, provide a home 
visit by a health-care worker, which many studies have 
recommended [47].
Table 2 Optimal early fasting glucose and 2-h OGTT for the determination of dysglycaemia
Receiver operating curve  
cutoff value (fasting and post-
prandial glucose) (mg/dl)






Prediabetes 78 0.73 (0.59–0.86) 70.6 63.1 33.3 89.1
Prediabetes 130 0.74 (0.61–0.87) 76.5 64.6 36.1 91.3
Diabetes 130 0.82 (0.66–0.97) 85.7 60.0 16.7 97.8
Diabetes 150 0.82 (0.66–0.97) 71.4 80.0 25 96.8
Diabetes 78 0.77 (0.61–0.91) 71.4 58.7 13.9 95.7
Diabetes 80 0.77 (0.61–0.91) 71.4 66.7 16.7 96.2
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The possibility of performing the screening while 
women are still in the hospital will most likely enhance 
the efficacy of detecting women at a higher risk for 
developing DM and will reinforce the need to return for 
individuals with a greater risk. Hospital sampling could 
overcome the barriers that currently prevent women 
from returning to health-care providers for investigation 
after 6  weeks. The characteristics of patients associated 
with higher rates of postpartum screening included older 
age, nulliparity, and higher income or education [15, 31]. 
Women who received prenatal care, were treated with 
insulin during pregnancy, or completed a postpartum 
visit were also more likely to receive a postpartum dia-
betes screening [15]. In the present study, 31.9 % of the 
women attended the postpartum follow-up examination, 
although all patients received reminders upon comple-
tion of the first OGTT. This response rate is similar to 
the lowest follow-up frequency [15, 31]. The most likely 
explanation for this result is that women in the stud-
ied population predominately belonged to low socio-
economic levels and thus, had lower levels of income 
and education. Sixty-four percent of patients that were 
included required insulin treatment, and 56 % of patients 
had more than 8 years of education. The problem of iden-
tifying DM after GDM, which may be of greater con-
cern than the choice of test itself, is the poor postpartum 
screening rate. Although counselling for the management 
of chronic disease may be challenging in the postpartum 
period, individuals sometimes express greater interest in 
their health during times of illness, and opportunities for 
early diagnosis should not be lost. During a brief discus-
sion, patients with elevated FPG and/or 2 h OGTT could 
be encouraged to partner with a provider and maintain 
long-term care, as well as to attempt lifestyle modifica-
tions. The concept of a “teachable moment” has been 
demonstrated for the case of smoking cessation, in which 
patients are more likely to quit smoking after health 
events, such as pregnancy, hospitalisation, and the diag-
nosis of cancer [39]. Thus, health events represent oppor-
tunities for health care providers to educate patients and 
encourage behaviour modifications [48–50].
The prevalence of diabetes in women after GDM in 
our study (8.5  %) is consistent with those previously 
described (5–14 %) [14, 15, 51–53]. The first OGTT iden-
tified more prediabetes than diabetes cases compared 
with the second OGTT (prediabetes 32.9 vs 20.7 %; DM 
3.7 vs 8.5 %). This result was most likely the result of the 
number of patients included. Larger cohorts are neces-
sary to recommend the OGTT at 48–72  h as a test for 
the early screening of postpartum women with GDM. 
Differences may also result from interference related to 
the hormonal changes that occur during this postpartum 
period [37–39]. A special hormonal milieu is observed 
between 48–72 h after birth. During pregnancy, the levels 
of oestrogen and progesterone increase greatly primarily 
because of placental production [40–43]. Following the 
removal of the placenta, these hormones fall sharply and 
reach pre-pregnancy levels on the fifty day postpartum 
[44]. Levels of cortisol, beta-endorphin, and β-HCG also 
decline during this period [45]. In women who do not 
breastfeed, prolactin returns to pre-pregnancy levels by 
3  weeks after delivery [46]. These hormones, which are 
counter-regulatory to insulin, contribute to increased 
insulin resistance in the early postpartum period.
This study had some limitations. Firstly, patients were 
included since 2008 and were classified according to 
two different criteria for GDM diagnosis (Carpenter 
Table 3 Comparison of sociodemographic categorical var-
iables of  pregnancy and  the newborn among  the women 
included and not included in the study
Included (%) Not included (%) P value
Age (years) 0.085
 10–20 0 5.26
 21–30 40.5 43.4
 31–40 50.6 48.7
 41–50 8.9 2.6
Ethnicity 0.86
 Caucasian 45.6 47.1
 Non caucasian 54.4 52.9
Gestational age at DMG diagnosis (weeks) 0.56
 ≤20 38.0 33.7
 ≥21 62.0 66.3
Insulin treatment 0.35
 Yes 64.6 57.5
 No 35.4 42.5
Previous history of DMG 0.008
 Yes 23.4 7.9
 No 76.6 92.1
BMI (kg/m2) 0.46
 <25 34.7 26.9
 25–29.9 31.9 39.7
 30–34.9 25.0 19.2
 35–40 8.3 12.8
 >40 0.0 1.3
Macrosomia 0.17
 Yes 14.9 24.5
 No 85.1 75.5
Type of delivery 0.14
 Vaginal 30.7 18.2
 Caesarean 69.4 81.8
DM familiar 0.69
 Yes 68.4 65.4
 No 31.6 34.6
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and Coustan and the IADPSG). Ikenoue et al. suggested 
that the IADPSG-defined GDM of one abnormal OGTT 
value indicates a less severe glucose intolerance, but may 
still signal a risk of requiring insulin when a first-degree 
family history of diabetes exists [54]. Our participants 
had a high prevalence of a relative with diabetes (68.4 %). 
Moreover, women who were discharged prior to 48  h 
were not included in this study. These patients most 
likely had a milder case of GDM and lowest prevalence 
of postpartum DM. Additionally, the sample size is small, 
therefore the 95  % CIs around the AUROC curves are 
quite wide.
Indeed, curtailing the rapidly increasing prevalence of 
early-onset diabetes is a formidable task for health-care 
practitioners. Additional efforts are necessary to identify 
these young women as early as possible because they are 
one of the best groups for which the implementation of 
a primary prevention strategy is most effective, not only 
for themselves but also for their offspring and family. 
Early postpartum screening for DM effectively identifies 
higher-risk women with previous GDM who require a 
referral for additional evaluation and management.
Conclusions
OGTT performed early in postpartum is a useful tool for 
identifying women with previous GDM who must per-
form an OGTT 6 weeks after delivery. A diabetes-screen-
ing cutoff of FPG of 78  mg/dl (4.3  mmol/L) and a 2-h 
OGTT of 130  mg/dl (7.2  mmol/L) effectively identified 
higher-risk individuals who require a referral for addi-
tional evaluation and should be further assessed in larger 
prospective studies.
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